Compass Pathways (CMPS) announced the U.S. Food and Drug Administration granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner’s National Priority Voucher program for treatment-resistant depression. “Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application, while maintaining FDA’s rigorous safety and efficacy standards,” the company stated.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways initiated with a Buy at B. Riley
- Compass Pathways enters collaboration with Osmind
- Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
- PBM, CMPS, ATAI: Psychedelic Biotech Stocks Soar after White House Order for Faster FDA Reviews
- Compass Pathways ‘commends’ White House Executive Order to accelerate research